fbpx

ERS interactive learning module on endoscopic lung volume reduction

  • Posted by Jenna Widdison
  • On December 1, 2013
This interactive case-based module illustrates the endoscopic treatment of severe emphysema by implantation of one-way-valves; emphasizes that an accurate patient selection is crucial for good outcome following ELVR; underlining that - despite of low morbidity and mortality - a strict monitoring of...
Read More

Pulmonx has launched its J-shaped endobronchial delivery catheter

  • Posted by Jenna Widdison
  • On November 1, 2013
The J-catheter is designed to assist in the placement of valves in difficult anatomy. Its preformed distal curvature may improve distal bronchoscope articulation by a minimum of 25% compared with the standard EDC, enabling access to difficult or tortuous anatomy
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • Posted by Chris Kellett
  • On August 27, 2012
August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial.
Read More

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • Posted by Chris Kellett
  • On January 10, 2012
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an independent review of clinical data from numerous studies including the recently completed Chartis multi-center study1 and the European VENT study (a randomized multi-center European trial of Zephyr EBV therapy)2.
Read More

Study Confirms Minimally-Invasive Pulmonx Therapy Effectively Treats Emphysema

  • Posted by Chris Kellett
  • On September 25, 2011
September 25, 2011, Amsterdam, Netherlands (ERS) – Pulmonx Inc. has just announced final results of its Chartis multi-centre study1, presented today at the European Respiratory Society’s 2011 Congress. This definitive data confirms that use of the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatmentsis the key to successful EBV treatment of emphysema.
Read More

Study Shows Revolutionary New Treatment from Pulmonx is Consistently Effective in Treating Emphysema

  • Posted by Chris Kellett
  • On March 18, 2011
May 18, 2011, Denver, CO (ATS) – Pulmonx Inc. has announced new clinical data from its Chartis multicenter study1, presented at the American Thoracic Society’s 2011 International Conference. This definitive data clearly demonstrates that by using the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatments physicians can consistently treat a broad spectrum of emphysema patients.
Read More

Pulmonx Reports Scientific Publication and Presentations Highlighting Key Advances in Emphysema Treatment

  • Posted by Chris Kellett
  • On September 27, 2010
September 27, 2010, Neuchâtel, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial).
Read More

Pulmonx Raises $32 Million for Launch of Emphysema Products

  • Posted by Chris Kellett
  • On February 22, 2010
ences Rollout of Breakthrough New Products Redwood City, CA USA (February 22, 2010) – Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr®Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System.
Read More